Calliditas Therapeutics Announces That The U.S. Patent And Trademark Office Issued Patent #11896719, Entitled "New Pharmaceutical Compositions," On January 24, 2024 With Validity As Of Today, February 13, 2024
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics announced the issuance of a new US patent (#11896719) for TARPEYO, covering a method of treating IgA nephropathy. This patent, valid from February 13, 2024, extends product protection until 2043 and has been filed for listing in the Orange Book. Calliditas plans to file corresponding patents in other territories, including Europe and China.
February 13, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calliditas Therapeutics has been granted a new US patent for TARPEYO, extending its protection until 2043 and indicating plans for international patent filings.
The issuance of a new patent for TARPEYO by the USPTO significantly strengthens Calliditas Therapeutics' intellectual property portfolio, providing extended market exclusivity until 2043. This development not only enhances the company's competitive position in the treatment of IgA nephropathy but also signals potential for increased revenue streams over a longer period. The intention to file for corresponding patents in other key markets like Europe and China further underscores the strategic importance of this patent, potentially opening up more significant global market opportunities for TARPEYO.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100